These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 8689867)

  • 21. Castration-refractory prostate cancer: New drugs in the pipeline.
    Schrijvers D; Van Erps P; Cortvriend J
    Adv Ther; 2010 May; 27(5):285-96. PubMed ID: 20532721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Advanced prostate cancer--a therapeutic dilemma?].
    Rübben H; Altwein JE
    Urologe A; 1987 Jan; 26(1):7-14. PubMed ID: 3576864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of metastatic prostatic cancer.
    Paulson DF
    Urology; 1985 Feb; 25(2 Suppl):49-52. PubMed ID: 3918376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
    Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New treatment strategies for hormone refractory prostate cancer.
    Redman BG; Pienta KJ
    Semin Urol; 1995 May; 13(2):164-9. PubMed ID: 7638474
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of progressive metastatic prostate cancer.
    Dawson NA
    Oncology (Williston Park); 1993 May; 7(5):17-24, 27; discussion 27-9. PubMed ID: 8512779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 31. Management of hormone refractory prostate cancer: current standards and future prospects.
    Oh WK; Kantoff PW
    J Urol; 1998 Oct; 160(4):1220-9. PubMed ID: 9751323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Other chemotherapy regimens including mitoxantrone and suramin.
    Siu LL; Moore MJ
    Semin Urol Oncol; 1997 Feb; 15(1):20-7. PubMed ID: 9050136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination chemotherapy following adrenal suppression in androgen- independent prostate cancer.
    Sella A; Flex D; Konichezky M; Sulkes A; Baniel J
    Eur Urol; 2000 Sep; 38(3):255-8. PubMed ID: 10940697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estramustine-based chemotherapy.
    Hudes G
    Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Complete androgen blockage in the treatment of metastatic prostate cancer].
    Matzkin H; Braf Z
    Harefuah; 1994 Mar; 126(5):260-3. PubMed ID: 8188104
    [No Abstract]   [Full Text] [Related]  

  • 36. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
    Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
    Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate].
    Culine S
    Prog Urol; 2002 Feb; 12(1 Suppl 2):31-5. PubMed ID: 11980025
    [No Abstract]   [Full Text] [Related]  

  • 38. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
    Samelis GF; Kalofonos H; Adamou A; Kosmides P; Skarlos D; Aravantinos G; Kiamouris C; Adimchi O; Fountzilas G; Dimopoulos AM
    Urology; 2005 Aug; 66(2):382-5. PubMed ID: 16098366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New perspectives in the drug therapy of hormone-resistant prostate cancer].
    Vorob'ev NA; Nosov AK; Vorob'ev AV; Moiseenko VM
    Vopr Onkol; 2010; 56(6):645-53. PubMed ID: 21395118
    [No Abstract]   [Full Text] [Related]  

  • 40. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
    Nakabayashi M; Ling J; Xie W; Regan MM; Oh WK
    Cancer J; 2007; 13(2):125-9. PubMed ID: 17476141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.